Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 117

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 117
---
 If a patentable invention arises from the research, we shall be responsible for funding the costs of the patent application.
Each party will be entitled to terminate the agreement in the event of a breach by the other party of its obligations under the agreement,
including, but not limited to, any payment failure, which is not remedied by the breaching party within 30 days of receipt of written
notice from the non-breaching party.

The Company has the exclusive right within 90
days from receipt of the final scientific report to exercise the option to obtain an exclusive worldwide license for the production and
commercialization of products with the underlying solution, and then the parties have up to 120 days to negotiate the specific terms
of the license. If the parties fail to negotiate a license within said time period, Yissum shall have no further obligations to the Company.

As of September 30, 2025, we have paid Yissum a total of $[226 ,000] pursuant to the Research and Option Agreement, as amended.

Subject to receiving a final report as to the
results of the research, we have the exclusive right to enter into a license agreement substantially on the same terms as our current
license agreement with Yissum. The research is continuing.

Our Growth Strategy

The Company plans to recruit an in-house development
team, with members working on several projects simultaneously to save costs and maximize knowledge and expertise. Where relevant stages
of the process will be subcontracted, with members of our team supervising their work.

We aim to progress with the continuous research
and developments activities, to develop additional applications using its technologies and to develop future product candidates and the necessary clinical trials until such time as they can be commercialized through licensing to
larger pharmaceutical companies which will take responsibility for completing advanced stages CTs trials, like Phase III and obtaining
regulatory approvals and marketing the products.

<div align='center'>75</div>

In connection with our Development of Nano Mupirocin, we are planning
to:

| ● | We are planning to seek                                                                                                               
 funding through a potential clinical collaboration agreement with the National Institutes of Health (NIH) and/or through partnerships 
 with U.S. government entities and non-profit organizations, such as BARDA and CARB-X in the United States and EIC Accelerator gran    
 programs in European Union for conducting Phase I -II Clinical Trials. As part of our efforts, in November 2024 we entered into a     
 Non-Clinical Evaluation Agreement (N